Effects of tafluprost and latanoprost on ocular blood flow and visual field

Effects of tafluprost and latanoprost on ocular blood flow and visual field - Effects of tafluprost and latanoprost on ocular blood flow and visual field

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002915

Enrollment

Registered

2009-12-25

Start date

2009-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

Tafluprost group: 3-year treatment once daily Latanoprost group: 3-year treatment once daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) At least one eye is POAG, the other eye can be under the same treatment or untreated during study period. 2) 20 or older than 20. 3) Both sexes. 4) Outpatient. 5) Provided signed, written informed consent. 6) Patients who can follow designated examination and observation. 7) IOPs of both eyes after washout are 25 mmHg or under 25 mmHg. 8) Patients who are untreated or completed designated washout.

Exclusion criteria

Exclusion criteria: 1)Patients with eye diseases except for glaucoma or mild cataract. 2) Patients with progressing and/or advanced glaucoma. 3) Patients with any corneal abnormality or other condition preventing reliable applanation tonometry. 4) Patients with active external ocular diseases, ocular inflammation or infection. 5) Patients with history of refractive surgery. 6)Patients with history of intraocular surgery within 6 months. 7) Smokers. 8) Patients who will use restricted medicines. 9) Patients whose ocular blood flow is unable to measure. 10) Patients whom investigators declare ineligible.

Design outcomes

Primary

Measure	Time frame
Ocular blood flow	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026